Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 181

1.

PAX8 (+)/p63 (-) immunostaining pattern in renal collecting duct carcinoma (CDC): a useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract.

Albadine R, Schultz L, Illei P, Ertoy D, Hicks J, Sharma R, Epstein JI, Netto GJ.

Am J Surg Pathol. 2010 Jul;34(7):965-9. doi: 10.1097/PAS.0b013e3181dc5e8a.

2.

The role of GATA binding protein 3 in the differential diagnosis of collecting duct and upper tract urothelial carcinomas.

Gonzalez-Roibon N, Albadine R, Sharma R, Faraj SF, Illei PB, Argani P, Ertoy D, Allaf ME, Netto GJ.

Hum Pathol. 2013 Dec;44(12):2651-7. doi: 10.1016/j.humpath.2013.07.006. Epub 2013 Sep 24.

PMID:
24071011
3.

p63, CK7, PAX8 and INI-1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high-grade tumours of the renal collecting system.

Carvalho JC, Thomas DG, McHugh JB, Shah RB, Kunju LP.

Histopathology. 2012 Mar;60(4):597-608. doi: 10.1111/j.1365-2559.2011.04093.x. Epub 2012 Jan 19.

PMID:
22260386
4.

PAX2(-)/PAX8(-)/inhibin A(+) immunoprofile in hemangioblastoma: A helpful combination in the differential diagnosis with metastatic clear cell renal cell carcinoma to the central nervous system.

Carney EM, Banerjee P, Ellis CL, Albadine R, Sharma R, Chaux AM, Burger PC, Netto GJ.

Am J Surg Pathol. 2011 Feb;35(2):262-7. doi: 10.1097/PAS.0b013e3182064d11.

PMID:
21263247
5.

Use of PAX8 and GATA3 in diagnosing sarcomatoid renal cell carcinoma and sarcomatoid urothelial carcinoma.

Chang A, Brimo F, Montgomery EA, Epstein JI.

Hum Pathol. 2013 Aug;44(8):1563-8. doi: 10.1016/j.humpath.2012.12.012. Epub 2013 Feb 28.

PMID:
23453625
6.

PAX2 and PAX8 expression in primary and metastatic renal tumors: a comprehensive comparison.

Ozcan A, de la Roza G, Ro JY, Shen SS, Truong LD.

Arch Pathol Lab Med. 2012 Dec;136(12):1541-51. doi: 10.5858/arpa.2012-0072-OA.

PMID:
23194047
7.

Diagnostic and prognostic impact of p63 immunoreactivity in renal malignancies.

Tuna B, Unlu M, Aslan G, Secil M, Yorukoglu K.

Anal Quant Cytol Histol. 2009 Apr;31(2):118-22.

PMID:
19402389
8.

[Expression of carbonic anhydrase IX, PAX2 and PAX8 and their association with clinicopathologic characteristics in renal epithelial tumors].

Zhang W, Yu WJ, Xia Y, Liu Y, Liu XL, Zhuang J, Li YJ.

Zhonghua Bing Li Xue Za Zhi. 2013 Jul;42(7):442-5. doi: 10.3760/cma.j.issn.0529-5807.2013.07.003. Chinese.

PMID:
24246861
9.

Immunohistochemical markers for the differential diagnosis of nephrogenic adenomas.

Quinones W, Ziober A, Yao Y, Bing Z.

Ann Diagn Pathol. 2013 Feb;17(1):41-4. doi: 10.1016/j.anndiagpath.2012.05.003. Epub 2012 Jun 5.

PMID:
22672805
10.

Primary carcinoma of renal calyx.

Williams PA, Mai KT.

Pathol Res Pract. 2013 Oct;209(10):654-61. doi: 10.1016/j.prp.2013.07.007. Epub 2013 Aug 12.

PMID:
23999038
11.

Immunohistochemistry for the novel markers glypican 3, PAX8, and p40 (ΔNp63) in squamous cell and urothelial carcinoma.

Gailey MP, Bellizzi AM.

Am J Clin Pathol. 2013 Dec;140(6):872-80. doi: 10.1309/AJCP4NSKW5TLGTDS.

PMID:
24225756
12.

Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study.

Tong GX, Yu WM, Beaubier NT, Weeden EM, Hamele-Bena D, Mansukhani MM, O'Toole KM.

Mod Pathol. 2009 Sep;22(9):1218-27. doi: 10.1038/modpathol.2009.88. Epub 2009 Jun 12.

13.

PAX8 expression in sporadic hemangioblastoma of the kidney supports a primary renal cell lineage: implications for differential diagnosis.

Zhao M, Williamson SR, Yu J, Xia W, Li C, Zheng J, Zhu Y, Sun K, Wang Z, Cheng L.

Hum Pathol. 2013 Oct;44(10):2247-55. doi: 10.1016/j.humpath.2013.05.007. Epub 2013 Jul 10.

PMID:
23849894
14.

A comprehensive analysis of PAX8 expression in human epithelial tumors.

Laury AR, Perets R, Piao H, Krane JF, Barletta JA, French C, Chirieac LR, Lis R, Loda M, Hornick JL, Drapkin R, Hirsch MS.

Am J Surg Pathol. 2011 Jun;35(6):816-26. doi: 10.1097/PAS.0b013e318216c112.

PMID:
21552115
15.

P63 immunoreactivity distinguishes upper urinary tract transitional-cell carcinoma and renal-cell carcinoma even in poorly differentiated tumors.

Langner C, Ratschek M, Tsybrovskyy O, Schips L, Zigeuner R.

J Histochem Cytochem. 2003 Aug;51(8):1097-9.

PMID:
12871991
16.

Malignant tumors with clear cell morphology: a comparative immunohistochemical study with renal cell carcinoma antibody, Pax8, steroidogenic factor 1, and brachyury.

Clayton EF, Ziober A, Yao Y, Bing Z.

Ann Diagn Pathol. 2013 Apr;17(2):192-7. doi: 10.1016/j.anndiagpath.2012.10.006. Epub 2012 Dec 4.

PMID:
23218904
17.

Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms.

Nonaka D, Tang Y, Chiriboga L, Rivera M, Ghossein R.

Mod Pathol. 2008 Feb;21(2):192-200. Epub 2007 Dec 14.

18.

High-grade carcinomas involving the renal sinus: report of a case and review of the differential diagnosis and immunohistochemical expression.

Young A, Kunju LP.

Arch Pathol Lab Med. 2012 Aug;136(8):907-10. doi: 10.5858/arpa.2012-0196-CR. Review.

PMID:
22849739
19.

PAX8 and PAX2 immunostaining facilitates the diagnosis of primary epithelial neoplasms of the male genital tract.

Tong GX, Memeo L, Colarossi C, Hamele-Bena D, Magi-Galluzzi C, Zhou M, Lagana SM, Harik L, Oliver-Krasinski JM, Mansukhani M, Falcone L, Hibshoosh H, O'Toole K.

Am J Surg Pathol. 2011 Oct;35(10):1473-83. doi: 10.1097/PAS.0b013e318227e2ee.

PMID:
21934480
20.

Diagnostic use of PAX8, CAIX, TTF-1, and TGB in metastatic renal cell carcinoma of the thyroid.

Cimino-Mathews A, Sharma R, Netto GJ.

Am J Surg Pathol. 2011 May;35(5):757-61. doi: 10.1097/PAS.0b013e3182147fa8.

Supplemental Content

Support Center